Recordati Group
CompanyItaly
Recordati Group develops 4 assets, the furthest approved (Osilodrostat). Mostly small molecule and peptide acting on CYP11B1; based in Italy.
- 4
- Assets
- Furthest stage
- Approved
- 6
- Trials
- 1
- Signal
Pipeline
4Aldosterone synthase (CYP11B2) inhibitor
Approved, Small molecule, CYP11B1, hypertension (Phase 3), Cushing's syndrome (Phase 3)
Pro-apoptotic peptide (fexapotide triflutate) causing targeted prostate cell death and tissue shrinkage.
Phase 3, Peptide, lower urinary tract symptoms
Combines calcium channel blockade and ACE inhibition to relax blood vessels and lower blood pressure.
Phase 2, Small molecule, essential hypertension
1 more asset
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials10
- Signals20
- Similar companies6